Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

Gambardella, V., Accordino, M. K., Bedard, P. L., Cervantes, A., Hamilton, E., Italiano, A., Kalinsky, K., Krop, I. E., Oliveira, M., Saura, C., Schmid, P., Turner, N. C., Varga, A., Fernandez-Saranillo, A., Jin, Y., Royer-Joo, S., Peters, U., Shankar, N., Schutzman, J. L., … Jhaveri, K. L. (2025). Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open, 10(7), 105303. https://doi.org/10.1016/j.esmoop.2025.105303
Authors:
V Gambardella
M K Accordino
P L Bedard
A Cervantes
E Hamilton
A Italiano
K Kalinsky
I E Krop
M Oliveira
C Saura
P Schmid
N C Turner
A Varga
A Fernandez-Saranillo
Y Jin
S Royer-Joo
U Peters
N Shankar
J L Schutzman
D Juric
K L Jhaveri
Affiliated Authors:
M K Accordino
K Kalinsky
Columbia Affiliation:
Author Keywords:
pi3k inhibitor
pik3ca-mutated
breast cancer
hormone receptor-positive
safety
elink
Publication Type:
Article
Unique ID:
10.1016/j.esmoop.2025.105303
PMID:
40513140
DOI:
10.1016/j.esmoop.2025.105303
Journal:
ESMO Open
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: